INTRODUCTION
Abnormalities of human Factor VIII (antihemophilic factor) are primarily associated with two congenital hemorrhagic disorders: classic hemophilia and von Willebrand's disease. Factor VIII was originally defined as the factor correcting the clotting defect in blood of patients with classic hemophilia (1) . This coagulant activity (VIII:C)' is now recognized to be associated with antigen (Factor VIII-related antigen, VIIIR:Ag), as detected by heterologous antisera (2) and with a factor correcting the prolonged bleeding time (3), the abnormal glass bead platelet-retention test (4, 5) and the defective ristocetin-induced platelet aggregation (6, 7) in von Willebrand's disease (von Willebrand factor, VIIIR:WF).2
Apart from the complexity of these Factor VIIIrelated activities, Factor VIII in plasma appears to be heterogeneous. This is manifested by the presence of multiple molecular forms showing differences in Factor VIII-related activities as well as in molecular weight (8-1 1).3'4 Factor VIII binding to platelets in the presence of ristocetin (platelet ristocetin-associated Factor VIII: PRA-VIII) has been shown to represent the most highly aggregated forms of Factor VIII, which contain VIIIR:WF. 3 The Factor VIII that is recovered in cryoprecipitate of normal plasma (cryo-VIII) also contains high molecular weight forms of Factor VIII and all VIIIR:WF, whereas the Factor VIII remaining in the cryosupernatant plasma (sup-VIII) consists of the forms of relatively low molecular weight, which have no VIIIR:WF (11) .
Studies concerning the survival of Factor VIII in humans have been based initially on the disappearance of VIII:C administered to classic hemophilia patients (12) (13) (14) . In this way the biphasic nature of the disappearance curve was discovered. The early data showed some discordance, but more recent studies have shown that the t1/2s are in the range of about [12] [13] [14] [15] [16] [17] [18] h. The introduction of the quantitative assay for VIIIR:Ag using heterologous antisera (2) allowed the analysis of the disappearance of Factor VIII on the basis of VIIIR:Ag. It was then reported that this VIIIR:Ag decreased more slowly than VIII:C after transfusion of normal cryoprecipitate into hemophiliacs (15) (16) (17) .
Infusion of a trace amount of radiolabeled Factor VIII might allow an accurate analysis of this phenomenon in a different way. Because the VIIIR:Ag represents the main protein constituent of the molecule, one may assume that the disappearance of proteinassociated radiolabel will reflect the catabolism of VIIIR:Ag. To our knowledge no data in humans obtained with well-characterized, purified, and radiolabeled Factor VIII have been reported. In this paper we describe the disappearance of 125iodine-labeled Factor VIII (1251-VIII) both in normals and in hemophiliacs. No significant difference was observed in the survival of VIII:C and 125I-VIII in transfused hemophiliacs. Basic catabolism of 1251-VIII was not significantly different in normals and hemophiliacs either. Further analysis made it possible to study the heterogeneity of Factor VIII by following the disappearance of various molecular forms in 125I-VIII: (a) the fraction of 1251-VIII that binds to platelets in the presence of ristocetin (1251-PRA-VIII), (b) the frac- tion that is cryoprecipitable when added to plasma (1251-cryo-VIII), and (c) the fraction that remains in cryosupernatant plasma (125j-sup-VIII). After infusion, the highest molecular weight forms of Factor VIII as present in PRA-VIII and cryo-VIII disappear more rapidly than the Factor VIII forms of lower molecular weight like those in sup-VIII.
METHODS
VIII:C was assayed in a one-stage clotting time assay using the kaolin-activated partial thromboplastin time as described by Veltkamp et al. (18) and modified by Bouma and Starkenburg (19) . Frozen (-70°C) reference plasma pooled from four normal donors was standardized against fresh pooled plasma of 40 normal donors (mean age 31.5 yr, ratio women/men = 1, nonpregnant women not taking oral contraceptives). 1 U of VIII:C is defined as the amount of VIII:C in 1 ml of the fresh normal plasma pool of 40 donors. The coefficient of variation was 8.2% (n = 10) (19) .
The VIIIR:Ag assay was carried out by the method of Laurell (20) with rabbit antifactor VIII (21) according to Over et al. (11, 22) . The dilution of antibody in the gel was chosen to produce precipitation peaks of 3-4 mm height for the eightfold diluted reference plasma. 1 U of VIIIR:Ag is defined as the amount present in 1 ml of a normal plasma pool of 40 healthy donors, frozen and stored at -70°C. The coefficient of variation was 8.0% (n = 36) for a normal plasma (22) .
VIIIR:WF was assayed as ristocetin cofactor activity using formalin-fixed platelets according to Macfarlane et al. (23 (26) . Freshly packed columns were treated with cryoprecipitate of four donors or 100 ml of normal plasma before use to prevent excessive adsorption of Factor VIII to the gel material. The void volume fractions were pooled and dialyzed against a mixture of 6.5 vol of distilled water and 3.5 vol of a saturated (at 4°C) ammonium sulfate solution, ad-justed to pH 7.0 with ammonia. The precipitate was spun down (3,500 g, 10 min, 4°C) and the supernate was removed except for the last 2 ml. The specific activities of the Factor VIII per milligram protein were 24.7±8.6 U (SD, n = 14) of VIII:C, 65.4±17.3 U (n = 9) of VIIIR:WF, and 70.9±20.0 U (n = 11) of VIIIR:Ag. Recoveries calculated from cryoprecipitate as starting material were 25.3±7.5% (SD, n = 8), 24.4±12.1% (n = 9), and 24.3±11.8% (n = 10), respectively. In most instances the precipitate was radiolabeled immediately after preparation.
Radiolabeling of Factor VIII was achieved with 125iodine by means of the lactoperoxidase method derived from Marchalonis (27) . 1 ml of the ammonium sulfate suspension of Factor VIII was centrifuged (10,000 g, 2 min, 20°C) in a swingout centrifuge (type 3200, Eppendorf Geratebau, Netheler and Hinz GmbH, Hamburg, West Germany). The supernate was removed carefully and the tube was dried with filter paper. The Factor VIII precipitate was dissolved in 0.35 ml of Michaelis (28) (Fig. 1) .
Gel chromatography of 12nI-VIII on Sepharose 2B (Pharmacia Fine Chemicals) was performed as described in the gel chromatography section (see below). No Survival of Radiolabeled Factor VIII in Humans r assay of PRA-VIII (see below). Although the Factor VIII was originally purified from cryoprecipitate and is therefore not entirely representative for the Factor VIII normally present in plasma, cryoprecipitation of normal plasma to which sterilized 125I-VIII was added showed that 12.4+4.6% (SD, n = 9) of the initial radioactivity in plasma (corrected for the presence of free '25iodine, see below) remained in the cryosupernatant plasma. This is not necessarily caused by the presence of a contaminant, because this percentage does not deviate from results obtained after a second cryoprecipitation of normal cryo-VIII, when analyzed for VIII:C.5
The PRA-VIII assay showed that 54.8±8.9% (SD, n = 7) of the initial radioactivity (corrected for the presence of free 125iodine) was bound to the platelets. When the plateletbound fraction ('25I-PRA-VIII) and the remaining supernatant fraction were analyzed by gel chromatography on 2% agarose, patterns of radioactivity were observed identical to the patterns of VIII:C and VIIIR:Ag when normal PRA-VIII and its remaining supernatant fraction were analyzed.
Large-pore polyacrylamide gel electrophoresis of nonreduced, sterilized 1251-VIII was carried out as described by Van Mourik et al. (8) . Acrylamide, methylene bisacrylamide, ammonium persulfate, and N,N,N1,N1,-tetramethylethylenediamine (TEMED) were purchased from Bio-Rad Laboratories (Richmond, Calif.). Gels were 4.35% with respect to acrylamide and 0.029% with respect to bisacrylamide. Sterilized 1251-VIII was dialyzed for 2 h at 4°C against 0.01 M sodium phosphate (pH 7.0) before application. Results are shown in Fig. 2 . A typical polydisperse pattern was obtained indicating the heterogeneity that exists even in the purified product. After slicing of the gel and counting of the radioactivity, 85% of the applied radioactivity was recovered in the gel, the rest presumably being free 125iodine. Nearly 80% was found in the same region as the stained Factor VIII protein, the rest being present mainly on the top of the gel. No radioactivity associated with low molecular weight material could be detected, free '25iodine excepted, which was recovered in the anode compartment.
125j-VIII was reduced as described by Van Mourik (29) using sodium dodecylsulfate (SDS, 1% wt/vol), urea (8 M), and dithiothreitol (DTT, 1% wt/vol; Calbiochem, San Diego, Calif.). After reduction, alkylation was carried out with a final concentration of 0.11 M iodoacetamide (Sigma Chemical Co.). Before polyacrylamide gel electrophoresis the whole reaction mixture was dialyzed overnight at 20°C against 0.01 M sodium phosphate buffer (pH 7.0) containing 0.1% (wtlvol) SDS, 0.1% (wt/vol) DTT, and 0.125M NaCl. Reduced samples were electrophoresed on 6.5% gels containing 1% methylenebisacrylamide in 0.37 M Tris-glycine (pH 9.5), 0.1% (wt/vol) SDS, and 0.1% (wtlvol) DTT. Electrophoresis was carried out at 2 mA for 30 min before sample addition. Samples of 100-350 ,ul containing 40% (wtl vol) sucrose were applied and electrophoresed for 0.5 h at 20°C at 1 mA per tube and for 1.5 h at 2 mA per tube. Results are shown in Fig. 3 . After slicing of the gel and counting of the radioactivity, about 90% of the applied radioactivity was recovered. The characteristic single subunit band of about 270,000 mol wt (29) contained the bulk of the recovered radioactivity. Solid phase immunoadsorption. The possible presence of a contaminant was further studied by submitting the preparation to solid phase immunoadsorption utilizing a highly specific antibody. The antiserum was raised in rabbits against the slow-moving component (21) of' highly purified Factor VIII at low ionic strength (8) . This particular component of Factor VIII had previously leen electrophoresed on polyacrylamide gel (8) making it unlikely that the antiserum was directed also to substances other than Factor VIII, appearing in the void volume of the Sepharose 6B column used for the purification of' Factor VIII. The y-globulins of' the antiserum were partially purified and immobilized to Sepharose beads (21) . For the control, y-globulins of normal rabbit serum were used. 1 ml of test samiiple was added to about 0.5 ml of antibody-coupled Sepharose (in 0.02 M Tris-HCl, pH 7.5, 0.10 M NaCl plus 5.1 mM trisodium citrate). The mixture was gently stirred for 6 h at 20°C and centrifuged (1,000 g, 5 min, 20°C) thereaf'ter. The supernate was removed from the Sepharose pellet and assayed for VIII:C, VIIIR:Ag, and radioactivity.
The Sepharose was washed five times with normal cryosupernatant plasma to remove nonspecifically adsorbed radioactivity and finally it was washed with buffer. The washed pellet and the supernates were counted for radioactivity. The total amount of radioactivity present in the washings was added to that of the first supernate.
Binding of' radioactivity was never complete. This was caused by the presence of' f'ree 125iodine (±1.5-12%) as (luantifie(l by protein precipitation with trichloroacetic acid (TCA) (see below). Additionally, Factor VIII was never bound completely, as established by measuring residual VIII:C and VIIIR:Ag in the supernate (±10-15%). Some radioactivity bound nonspecifically (±1.5-3%), which was shlown by counting the washed control Sepharose. After correction for these values, plasma samples before, and at various times after, inf'usion (obtained from five infusion experinments) contained between 90 and 108% of radioactivity associated with VIIIR:Ag (mean± SD: 99.4±5.2%, n = 12). No indication was f'ound f'or a smaller percentage in later (23-h) postinflsion samples as compared to preinfusion or 15-inin samples.
Normals and Patients
Normals were six male volunteers, physicians, or biochemists of' the Department of Hematology. Patients were four severely affected hemophiliacs and two moderately severe hemophiliacs (W. K.: VIII:C 3%; R. M.: VIII:C 6%). All patients had been treated by us for a long time. No trace of' an inhibitor had been demonstrated on any of several occasions. Ages of the volunteers ranged from 25 to 40 yr. The investigation was submitted to the Committee on Medical Ethics of our hospital and approved. The nature, purpose, and possible risks of' the study were fully explained to each subject before obtaining his voluntary consent. All persons received an intravenous injection of 200 mg Nal 2-4 h before the injection of 1251-VIII. Lugol's solution, 10 drops three times daily, was used during 1 wk after administration. Four of the patients with hemophilia received cryoprecipitate f'rom 20 donors from the same source as used for purification of Factor VIII. This material was infused during 3/4-1 h. 1251IVIII was injected within 15 min after the end of the cryoprecipitate infusion. In general, 15 ,tl of the infused '251_ VIII solution was mixed with 15 ml of fresh plasma of the volunteers collected before infusion in order to make it comparable to the postinfusion samples. This preinfusion plasma was characterized similarly to the plasma samples obtained after infusion.
'251-VIII was injected intravenously. The quantity administered was determined by weighing the syringe before and after injection. The injected quantities ranged from 0.2 to 3.2 U of VIII:C (mean 1.1 U, n = 11), 3.7 to 16.4 U of VIIIR:WF (mean 8.2 U, n = 4), and 1.2 to 12.3 U of VIIIR:Ag (mean 5 (30) and fibrinogen (31) .
Assay of '251-PRA-VIII was performed according to x [body surface area in m2] -0.14 [32] ). The formula used for the body surface area calculation was that of Boyd (33 Fig. 4 . The survival of 1251-VIII can be described as a double exponential curve. In the first hours after infusion a rapid disappearance of Table I ) was lower than is usually reported for VIII:C (14, 36, 37, and Table VI ). This may be due to rapid clearance of Factor VIII denatured during the preparation procedure. Although the recovery did not correlate with the VIII:CIVIIIR:Ag ratio, a low recovery was found in the experiments with a low ratio (W. K. and J. W., Table I ).
The percentage of 125I-VIII that disappeared in the initial phase (Table I ) was computed by extrapolation of both phases to the y-axis (see Fig. 4 Survival of 1251-PRA-VIII. The survival of 1251-PRA-VIII, i.e. the fraction of 125I-VIII binding to platelets in the presence of ristocetin, was studied. A rapid disappearance of the radioactivity in this fraction was observed. This limited the number of time-points available for computation to 5-8 in most instances. The kinetic data are therefore less reliable than those obtained for whole plasma.
The recovery of 125I-PRA-VIII (mean 69.7%, n = 4) tended to be lower, but was not significantly different from that of total 125I-VIII. ing the time needed till only 10% ofthe initial 1251-PRA-VIII value was left (Table III) . This overall disappearance of 125I-PRA-VIII was faster in the normals than in the transfused hemophiliacs (Mann-Whitney, P < 0.01). This shorter survival of 125I-PRA-VIII in nontransfused subjects was also apparent when analyzed in a different way. Calculation of the ratio of the second tl/2 of 125I_
PRA-VIII over that of total 125I-VIII showed that a significant smaller ratio was obtained in the nontransfused subjects (t test, P < 0.005). The short survival of 1251-PRA-VIII suggested that the disappearance of this material might be responsible for the rapid first phase of total 1251-VIII (Fig. 4) . When the data of 125I-PRA-VIII were subtracted from the I25I_VIII values in total plasma, single exponential curves in all but three experiments (J. S., J. W., and M. H.) were obtained. This suggests that the disappearance of radioactivity in the first phase of the survival curve of 125I-VIII is mainly due to the disappearance of 1251-PRA-VIII.
Survival of 1251-cryo-VIII. The amount of 1251-VIII present as cryo-VIII and as sup-VIII at different times after injection was determined as described in Methods. The recovery of 125I-cryo-VIII was slightly (about 2%) but significantly (paired t test, P < 0.025) higher than found for total 125I-VIII. The amount of 1251_ VIII recovered in cryoprecipitate ofthe samples at zero disappearance time was 88.8+5.3 (SD, n = 7) and 89.6+4.7% (SD, n = 7) of 15-min postinfusion samples. These values were corrected for the presence of free 125iodine. The disappearance curve of 1251-cryo-VIII was double exponential (Fig. 4) . The t1/2s of both phases were similar in the normals and in the hemophiliacs (mean 2.5 h for the first tl2 and 16.3+±2.6 [SD, n = 12] for the second t1/2, Table IV ), but they are shorter than those of total 1251-VIII (paired t test, P < 0.025 for the first tl/2 and P < 0.001 for the second tl/2).
The percentage of 1251-cryo-VIII removed in the first phase was different between nontransfused and transfused subjects (46.4 +9 .6% [SD, n = 8] and 29.8+14.6% [SD, n = 4], respectively; t test, P <0.05). The percentage of 125I-cryo-VIII disappearing in the first phase was larger than that of total 1251-VIII (paired t test, P < 0.01), but equal to that of 125I_PRA-VIII. Also the t1,2s of the first phase of 1251-cryo-VIII and 1251-PRA-VIII did not differ. The tl,2 ofthe second phase was larger for 125I-cryo-VIII, however (paired t test, P < 0.001).
Survival of 125_-sup-VJII. t Determined by extrapolation (see Table I ). 5 The values are probably not in a normal distribution. Not transfused (see Table I ).
P < 0.025) than found for total 1251-VIII. The percentage of 125I-VIII remaining in cryosupernatant plasma was 11.2+5.3% (SD, n = 7) at zero disappearance time and 10.4+±4.7% (SD, n = 7) at 15 min postinfusion. Because of the small percentage these values were corrected for the presence of free 125iodine. This correction was carried out for seven disappearance curves. These were single exponential in four cases. The t1/2s of the monophasic curves or of the second phase of the 1
The corresponding values for '25I-VIII in whole plasma (Table I) are given in parentheses.
This should then lead to a relative increase of the percentage of'25I-sup-VIII oftotal 1251-VIII. 11. staining. In general, the amount of radioactivity in the immunoprecipitate was too small to detect the expected shift of radioactivity toward more anodally migrating forms of Factor VIII at later times after infusion. Excretion of 125iodine in urine. The urine excretion of'25iodine was followed in five individuals (J. O., J. W., K. S., R. M., and A. M.). A very consistent picture was obtained. The sum of radioactivity in plasma and the radioactivity excreted decreased for 6 to 10 h, but returned to about 70% of the radioactivity infused (71.8±7.1% [SD, n = 5]) after 66 h.
DISCUSSION
Transfusion studies of 1251-VIII into normals and hemophiliacs were undertaken to compare the disappearance of the radiolabel with that of VIII:C and to study the heterogeneity of Factor VIII. Our results indicate that no significant difference was present in the disappearance of 125I-VIII and VIII:C in transfused hemophiliacs nor in the catabolism of 125I-VIII comparing normals and hemophiliacs. Evidence was obtained that the highest molecular weight forms of Factor VIII as present in PRA-VIII and cryo-VIII disappear more rapidly than the lower molecular weight forms, as present in sup-VIII.
The overall shape of the disappearance curve of 1251_ VIII (Fig. 4) in hemophiliacs as well as in normals conformed to the disappearance of VIII:C in the hemophiliacs and to the data reported in the literature (12-14, 36, 37) . In the first hours after infusion a rapid disappearance of radioactivity was observed, followed by a second phase characterized by a slower decrease. The t112 of this phase was slightly longer than usually reported fbr VIII:C in transfused hemophiliacs (12, 13, 36, 37) . In this study also the t112 of the second phase of VIII:C seemed to be shorter (Table VI) . The curves were so similar, however, that we feel that this difference is of no importance in comparison to the data reported by others for the half-disappearance time of VIII:C and VIIIR:Ag in transfused hemophiliacs (15) (16) (17) . Analysis of the survival of VIIIR:Ag in the four transfused hemophiliacs in this study showed that in A.
V. and R. M. the disappearance was similar to that of 125I1 VIII (second t1/2: 15 and 17 h, respectively). In W. K. and J. Ma., a tl2 of 45 and 54 h, respectively, was found.
These discrepancies were probably caused by the low accuracy of the measurements, which was presumably due to the high baseline level of VIIIR:Ag. Therefore, the data do not permit a conclusion concerning the survival of VIIIR:Ag.
The first phase is at least in part due to the disappearance of the highest molecular weight forms of Factor VIII. Evidence hereof was obtained from the observation that 1251-PRA-VIII disappeared faster than 125I-VIII (Fig. 4 , Tables I and II) , and subtraction of 1251-PRA-VIII values from 125I-VIII values produced in most cases a single exponential curve that conformed largely to the second phase of '251-VIII. Previous studies had shown that PRA-VIII consists of the most highly aggregated forms of Factor VIII, possessing all VIIIR:WF present in plasma. 3 In addition, by means of cryoprecipitation of plasma ofthe recipient at different times, it was shown that 1251_ cryo-VIII (Table IV) had a shorter tl2 than total '251-VIII (Table I) , and 125I-sup-VIII lived longer (Fig. 4 , Table  V) . Furthermore, survival curves of 125I-sup-VIII tended to be monophasic. Previous studies from our laboratory have shown that sup-VIII represents forms with lower apparent molecular weight without VIIIR:WF (1 1). This suggested again that the higher molecular weight forms disappear faster. This was further substantiated by gel chromatographic analysis, which showed a preponderance of smaller forms at later times (Fig. 5) . In addition, the observation that VIII:C in cryosupernatant plasma ofthe transfused hemophiliacs also had a longer tl2 than VIII:C in whole plasma or cryoprecipitate supported the conclusion of a longer survival of sup-VIII.
An alternative explanation for the biphasic nature and the longer survival of lower molecular weight forms of Factor VIII might be a continuous conversion of higher molecular weight forms into forms of lower molecular weight. Some indication hereof was obtained in the hemophiliacs A. V., R. M., and A. M., who showed a slight absolute increase (A. V. and R. M.) or a constant amount (A. M.) of 125I-sup-VIII during 19,9, and 31/2 h after infusion, respectively. Comparison of the ratio of the t,,2 of 125I-sup-VIII over that of total 125I-VIII showed that this ratio was higher for the transfused hemophiliacs A. V. and R. M. as compared to the other five persons (three normals and two nontransfused hemophiliacs, Tables I and V) . This observation was supported by results obtained in similar studies with von Willebrand's disease patients.6 This higher ratio would suggest that transfusion decreased the removal of 125I-sup-VIII. However, the absolute increase in 1251-sup-VIII, in combination with the longer overall survival of 125I-PRA-VIII (Table III) , supported an alternative explanation. A previous transfusion with cryoprecipitate may decrease the removal of high molecular weight forms, like PRA-VIII. Thus, the concentration of these forms thereby decreases more slowly. This will then lead to an absolute or relative increase of lower molecular weight Factor VIII forms, like sup-VIII.
The conversion process, however, if really existing, will most certainly not be the only one responsible for removal of high molecular weight forms, as the overall disappearance of 1251-VIII showed that a large amount ofradioactivity was rapidly eliminated from the circulation (Fig. 4) . The urine values also indicated that a certain amount of radioactivity was sequestered in the body. A possible location of the compartment into which high molecular weight forms may disappear is the reticuloendothelial system. This concept was supported by the more rapid removal of the highest molecular weight forms and by the observation that a preceding transfusion of cryoprecipitate decreased the amount disappearing in the first phase for 1251-VIII and 1251-cryo-VIII and that it increased the overall survival of '25I-PRA-VIII. However, the latter effects were not highly significant (P = +0.07, P <0.05, P <0.05, respectively), but results obtained in von Willebrand's disease patients5 supported this concept. This effect of a previous transfusion suggests that the compartment was saturable. In this respect, it is of particular interest that the disappearance of VIII:C is monophasic in multiply transfused (13) or continuously transfused (38) hemophiliacs.
The concept of the reticuloendothelial system being responsible for the first phase is supported by a recent study of Sodetz et al. (39) , who infused 125iodine-labeled human Factor VIII into rabbits. Blocking of the reticuloendothelial system diminished the percentage removed in the first phase. It was also found that a plasma sample containing 1251-VIII, obtained from a rabbit at a time after which the first rapid removal (of the highest molecular weight forms?) had occurred, did not show a significant first phase again, when reinfused into a second rabbit. In addition, this experiment excluded the possibility of an equilibrium-distribution phenomenon toward extravascular compartments. The high molecular weight nature of Factor VIII is probably a serious impediment for passage to the extravascular space. Although it was found that Factor VIII may be bound by platelets to some extent (40) (41) (42) ,7 no Factor VIII was taken up by the platelets of transfused, severe von Willebrand's disease patients (43) (44) (45) . Similarly, no Factor VIII was detected in the endothelium after transfusion of such patients (46) . As a consequence, the extravascular compartment must be very small for Factor VIII.
The loss of about 30% of radioactivity within the first 15 min after infusion could not be accounted for merely by removal of the highest molecular weight forms, as was established by extrapolation of the survival curves to zero disappearance time. This may be caused by rapid clearance of some denatured Factor VIII, present in the 1251-VIII preparation.
The presence of free 125iodine also contributes to a low recovery, due to its large distribution volume.
In conclusion, no basic difference in the survival of 1251-VIII existed between normals and hemophiliacs. Our data show a preferential removal of high molecular weight forms of Factor VIII, as can also be inferred from studies in transfused swine with von Willebrand's disease (47) . The long survival of the low molecular weight forms as present in sup-VIII may be a real phenomenon, but it may also be caused by continuous generation of low molecular weight forms like sup-VIII, from higher molecular weight forms, like PRA-VIII and cryo-VIII. The data do not allow, however, a choice between the two alternatives. Direct estimation of the t1/2 of sup-VIII by infusion of this material will be needed to solve this question, which is of importance for the relation between the various Factor VIII forms present in plasma.
